Mangafodipir is the only MRI contrast agent with a potential to quantify alterations in calcium handling and contractility in heart diseases. With mangafodipir-enhanced MRI (MEMRI), physicians can measure the rate of influx of manganese into cardiomyocytes which is a direct measure of calcium channel activity. Reduced calcium channel activity is found in ischemic heart disease, in dilated and hypertrophic cardiomyopathies and in heart failure. ICT’s procedure will be a game changer for MR imaging of the heart.
IC Targets has initiated a preclinical study to validate a novel MRI procedure which will enable characterization of calcium handling at a cellular level. We are planning to conduct clinical studies in patients suffering from heart failure with preserved ejection fraction (HFpEF), which represents about 50% of heart failure cases and where the need for improved diagnosis and treatment is most urgent.
More than 50 million patients in the seven major markets have heart disease. The annual growth rate is 1,4% and heart disease is the leading cause of death in the USA and Europe. Our long-term goal is to get approval for MEMRI in all common heart diseases where calcium handling may be altered. Assessment of calcium channel activity with MEMRI will provide a tool for better diagnosis, improved selection of therapy and monitoring of treatment efficacy in these patients.
IC Targets’ procedure is covered by granted patents and additionally filed patent applications for the new uses of mangafodipir.